Animal modeling dual diagnosis schizophrenia: sensitization to cocaine in rats with neonatal ventral hippocampal lesions

Biological Psychiatry
R Andrew Chambers, Jane R Taylor

Abstract

Increased substance disorder comorbidity in schizophrenia may reflect greater vulnerability to addictive processes because of inherent neurocircuit dysfunction in the schizophrenic brain. To further explore this hypothesis, we used neonatal ventral hippocampal lesions (NVHL) as a rat model of schizophrenia and assessed locomotor sensitization to cocaine (15 mg/kg) in adulthood. The NVHL animals showed greater activity in response to an initial cocaine injection compared with sham and saline-treated groups. With daily cocaine injections over 7 days, NVHL rats showed elevated locomotor sensitization curves with greater fluctuations in the intersession changes in activity between days 4 and 7. In a single session 4 weeks later, NVHL compared with SHAM rats showed maintenance of cocaine-associated hyperactivity, as if superimposed on long-term sensitization effects present in both groups. In a neurodevelopmental model of schizophrenia, the locomotor effects of cocaine were augmented on initial and repeated doses, with emergence of irregularity in sensitization-related changes in activity in the short term and perseverance of augmented effects in the long term. Altered patterns of behavioral sensitization, as a possible correlate of...Continue Reading

References

Mar 1, 1975·The American Journal of Psychiatry·R M Post
May 1, 1995·The American Journal of Psychiatry·S E ArnoldJ Q Trojanowski
May 1, 1994·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·B K Lipska, D R Weinberger
Aug 1, 1993·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·B K LipskaD R Weinberger
Sep 1, 1993·Brain Research. Brain Research Reviews·T E Robinson, K C Berridge
Feb 15, 1993·Biological Psychiatry·B BogertsS Masiar
Jan 1, 1996·New Directions for Mental Health Services·B J Cuffel
Dec 1, 1996·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·R A ChambersE D Levin
Jul 18, 1997·Brain Research. Developmental Brain Research·G K WoodD R Weinberger
Jan 1, 1997·Pharmacology & Therapeutics·J P KellyB E Leonard
Apr 21, 1998·The Journal of Neuropsychiatry and Clinical Neurosciences·N N BoutrosD Quinlan
Nov 7, 1998·The Australian and New Zealand Journal of Psychiatry·N Siegfried
May 18, 1999·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·G GreckschB Bogerts
Mar 4, 2000·Behavioural Brain Research·A Becker, G Grecksch
Sep 6, 2000·Psychiatric Services : a Journal of the American Psychiatric Association·R E Drake, M A Wallach
Aug 31, 2001·Biological Psychiatry·R A ChambersD W Self
Dec 26, 2001·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Taco J De VriesLouk J M J Vanderschuren
Dec 5, 2002·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·R Andrew Chambers, David W Self
Apr 12, 2003·Trends in Neurosciences·Gregory L GerdemanDavid M Lovinger
Jun 5, 2003·The American Journal of Psychiatry·R Andrew ChambersMarc N Potenza
Apr 6, 2004·Synapse·R Andrew ChambersJane R Taylor

❮ Previous
Next ❯

Citations

Feb 10, 2012·Nicotine & Tobacco Research : Official Journal of the Society for Research on Nicotine and Tobacco·Jill M WilliamsNeal L Benowitz
Mar 1, 2007·Journal of Dual Diagnosis·R Andrew Chambers
Apr 11, 2014·PloS One·Owen G O'DalySukhwinder S Shergill
Apr 10, 2013·Neuroscience and Biobehavioral Reviews·Enoch NgJohn C Roder
Oct 2, 2007·Progress in Neuro-psychopharmacology & Biological Psychiatry·Stacy A Castner, Graham V Williams
Jun 19, 2007·Neuroscience and Biobehavioral Reviews·R Andrew ChambersMarc N Potenza
May 20, 2009·Hippocampus·Jean-Baptiste BertrandMarie-Françoise Suaud-Chagny
Jan 28, 2010·The European Journal of Neuroscience·M J García-FusterH Akil
Aug 29, 2006·Pharmacology, Biochemistry, and Behavior·Susan K ConroyR Andrew Chambers
Oct 29, 2005·Pharmacology, Biochemistry, and Behavior·Osnat Ben-ShaharAaron Ettenberg
Dec 28, 2010·Behavioural Brain Research·S A BergR Andrew Chambers
May 26, 2016·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Jana Ruda-KucerovaVincenzo Micale
Dec 23, 2008·Behavioural Brain Research·Kuei Y TsengBarbara K Lipska
Sep 16, 2005·The Journal of Pharmacology and Experimental Therapeutics·Hana Hammad, John J Wagner
Feb 7, 2020·Current Pharmaceutical Design·Matthew M ClasenTerry L Davidson
Apr 19, 2017·Schizophrenia Research·Jibran Y KhokharAlan I Green

❮ Previous
Next ❯

Related Concepts

Related Feeds

Amygdala and Midbrain Dopamine

The midbrain dopamine system is widely studied for its involvement in emotional and motivational behavior. Some of these neurons receive information from the amygdala and project throughout the cortex. When the circuit and transmission of dopamine is disrupted symptoms may present. Here is the latest research on the amygdala and midbrain dopamine.

Amygdala: Sensory Processes

Amygdalae, nuclei clusters located in the temporal lobe of the brain, play a role in memory, emotional responses, and decision-making. Here is the latest research on sensory processes in the amygdala.